Canaccord Genuity conference top picks

Canaccord Genuity has issued a report of its top picks – two value ideas and four growth ideas – coming out of its 31st annual Global Growth conference held last week in Boston. “While the overall equities markets’ direction may be a source of uncertainty in the near-term, we found our companies steadfastly holding to [...]

Canaccord ups target on IMRIS

Canaccord Genuity has raised its price target on IMRIS (NASDAQ:IMRS; TSX:IM) to $10.50 (U.S.) from $9, saying the stock warrants a premium multiple to the small-cap med-tech peer group, given its growth profile. The stock closed at $7.31 on Monday. Analyst Jason Mills writes that IMRIS offers investors a “rare opportunity to participate in a [...]

IMRIS prices $52.5 million offering

IMRIS (TSX:IM; NASDAQ:IMRS) priced a public offering of 10.5 million common shares at $5 (U.S.) a share to raise $52.5 million in connection with listing its shares on the NASDAQ Global Market. An additional 500,000 shares are being sold by a certain selling shareholder of IMRIS at the same price. Canaccord Genuity and Lazard Capital [...]

IMRIS sells MRI product to UCSF Medical Center

IMRIS (TSX:IM) has sold its IMRISneuro system to the University of California San Francisco Medical Center, featuring a fully integrated multi-room system with on-demand intraoperative MRI capabilities. When not in use for intraoperative imaging, the MR scanner would be available for diagnostic imaging. “In our commitment to providing the best care to our patients, we [...]

IMRIS to list on Nasdaq and sell stock

IMRIS (TSX:IM) has filed a registration statement as part of an IPO in the U.S. and has received conditional approval to list its common shares on the NASDAQ Global Market under the symbol IMRS. IMRIS proposes to offer 10 million common shares and certain selling shareholders propose to offer 3.7 million shares through a syndicate [...]

IMRIS, Varian in pact with Saudi Arabia

The Saudi Arabian National Guard Health Affairs (NGHA) in Jeddah has signed an agreement with Varian Medical Systems (NYSE:VAR) and IMRIS (TSX:IM) to develop and build a facility for magnetic resonance-guided radiation therapy. Under the accord, Varian and IMRIS will supply a cancer treatment solution that combines IMRIS’ movable MRI technology with Varian’s latest linear [...]

IMRIS sells IMRIScardio to Melbourne hospital

IMRIS (TSX:IM) has sold its IMRIScardio machine to the Royal Children’s Hospital in Melbourne, Australia, making it the first paediatric hospital in the world with the capabilities of both IMRIScardio and IMRISneuro for cardiovascular procedures, an operating room for neurosurgery and a diagnostic centre. “The IMRIS system is the first solution in the world that [...]

IMRIS to develop radiation treatment with Varian

IMRIS (TSX:IM) and Varian Medical Systems (NYSE:VAR) have agreed to co-develop a radiation therapy suite that couples IMRIS’ magnetic resonance imaging technology with Varian’s TrueBeam radiotherapy system for use in treating a variety of cancers. “We are seeking to augment physicians’ ability to target cancerous tissue very precisely, even in areas of the body that [...]

Australia clears sale of new IMRIS devices

IMRIS (TSX:IM) has received clearance from Australia’s Therapeutic Goods Administration for the marketing of the company’s newest products, IMRISNV and IMRIScardio. IMRISNV and IMRIScardio are the first systems in the world to allow both MRI and X-ray angiography in a single suite without the need to transport the patient between modalities.  The devices have been [...]

IMRIS and Siemens in long-term OEM pact

IMRIS (TSX:IM) has signed a new master OEM agreement with Siemens Healthcare to support its continued growth and expansion of image-guided therapy solutions. Under the five-year accord, which renews and amends an earlier arrangement between the two companies, Siemens will supply magnetic resonance imaging scanners and angiography systems as component parts for IMRIS’ fully integrated [...]

Next Page »